Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
THEMATICAL SERIES

Different disease, same challenges: Social determinants of tuberculosis and COVID-19

R. Duarte a,b,c,d,e, A. Aguiar a, M. Pinto b,e, I. Furtado f, S. Tiberi g,h, K. Lönnroth i, G.B. Migliori i

a EPI Unit, Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal
b Unidade de Investigação Clínica da Administração Regional de Saúde do Norte, Porto, Portugal
c Departamento de Ciências de Saúde Pública, Ciências Forenses e Educação Médica, Universidade do Porto, Porto, Portugal
d Serviço de Pneumologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
e Faculdade de Psicologia e Ciências da Educação, Universidade do Porto, Porto, Portugal
f Serviço de Infecciology, Centro Hospitalar do Porto, Portugal

Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK
Department of Global Public Health, Karolinska Institute, Stockholm, Sweden
Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti CliniciScientifici Maugeri, IRCCS, Tradate, Italy

Received 2 February 2021; accepted 3 February 2021
Available online 19 February 2021

KEYWORDS
TB;
COVID-19;
Social determinants;
Good practices;
Global health response

Abstract Infectious diseases, such as tuberculosis (TB) and the novel coronavirus (COVID-19) relate to environmental factors, understanding of which is essential to inform policy and practice and tackle them effectively.

The review follows the conceptual framework offered by the World Health Organization Commission on Social Determinants of Health (defined as ‘all those material, psychological and behavioural circumstances linked to health and generically indicated as risk factors’ in the conventional epidemiological language’). It describes the social factors behind TB and COVID-19, the commonalities between the two diseases, and what can be learned so far from the published best practices.

The social determinants sustaining TB and COVID-19 underline the importance of prioritising health and allocating adequate financial and human resources to achieve universal health coverage and health-related social protection while addressing the needs of vulnerable populations. Rapid and effective measures against poverty and other major social determinants and sources of inequality are urgently needed to develop better health in the post-COVID-19 world.

© 2021 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction to social factors

Infectious diseases may be conceptualized as ecological, biological and social events given their ability to influence life at several levels and dimensions. Some of the social and economic factors that concur to shape human behaviour pose considerable challenges for preventing and controlling infectious diseases. Among the most described and explored are population density, setting (urban/rural), and population growth. Like other well-established infectious diseases, such as tuberculosis (TB), the prevention and control of 2019 novel coronavirus (COVID-19) also relates to environmental factors. To identify these and to assess their association with the features of the COVID-19 pandemic it is essential to inform policy and practice and address this problem in more practical terms.

In the present article, we follow the conceptual framework offered by the World Health Organization (WHO) Commission on Social Determinants of Health, which defines them as “all those material, psychological and behavioural circumstances linked to health and generically indicated as risk factors’ in the conventional epidemiological language”. We describe the social factors behind TB and COVID-19, commonalities between the two diseases, and what we can learn so far from the published best practices.

Methods

A non-systematic search of the English-written scientific literature was carried out on PubMed using the following keywords: 'social determinants', 'COVID-19' and 'tuberculosis'. No time restrictions were applied and the selected publication types included clinical trials, observational studies, cohort studies and literature reviews. The information retrieved from the above search was used in the compilation of the present article.

Social factors and TB

TB is a chronic infectious disease and is one of the leading causes of mortality worldwide. Over a century ago, Virchow recognized it as a social disease and, although TB rates worldwide are declining, they remain very high. Thus, in this sense, TB continues to be a social disease inextricably linked with poverty.

Global TB control and the respective research strategy have during long periods focused mainly on a biomedical approach rather than a socioeconomic response to the epidemic. Even though it may cure millions of people, an exclusively biomedical response has not been enough to eliminate TB. A more holistic approach, addressing not only biomedical responses but also the broader environmental determinants of this disease, is required.

Personal experiences, perceived aetiology of the disease, stigma, beliefs and attitudes associated with TB are meaningful in health-seeking behaviour. Many studies have assessed what factors may affect it in different sociocultural settings. Poor perception of health problems, care-associated costs, and physical distance to healthcare facilities are obstacles to seeking care among TB patients. Furthermore, socioeconomic status, poor housing and environmental conditions, food insecurity and malnutrition, alcohol consumption, smoking, drug consumption, comorbidities (e.g., HIV/AIDS, diabetes, mental disease), and incarceration seem to predispose people to developing TB.

These social factors have been described as influential on the access to TB diagnostic and treatment. A modelling study published in 2018 to support the WHO End TB Strategy demonstrated that reducing extreme poverty and expanding social protection is estimated to reduce TB incidence by up to 84.3%.

Social factors and COVID-19

The outbreak and rapid global diffusion of the COVID-19 continue to occupy prominent positions in social media, research, and policy agendas worldwide. As expected, and based on previous infectious disease outbreaks, such impacts have been especially dire in particular contexts and particular groups, with broad-ranging and systemic consequences. In countries everywhere, infection rates of certain diseases are disproportionately high in socially disadvantaged and underserved groups, negatively impacting health and well-being and driving individuals and communities into cycles of illness and poverty.

Issues such as inadequate health care, especially for poor and low-wage workers without paid sick days or insurance; lack of proper sanitation and infrastructure; and exposure to other diseases, pests, and environmental pollutants, constitute obstacles that can increase vulnerability to infection. Regarding the consequences of the pandemic on individuals and communities, not to mention societies at large, healthcare access, quality, and capacities are fundamental considerations. Protection against income loss is an important enabler for following public health advice, such as staying home when sick or quarantine after exposure, and people living in the context of insecure employment with poor social security have increased risk of both infections and social impact of disease.

Demographic, socioeconomic, and geographical factors that characterize different populations are significant predictors of disease transmission and effects.

Many social determinants of health – including poverty, physical environment (e.g., smoke exposure, homelessness), and racial and ethnic discrimination – can considerably affect COVID-19 outcomes. This way, social determinants have an impact on health by affecting those who get sick and the community as a whole. Not everyone has been equally affected by the COVID-19 pandemic, and the same can be affirmed about TB or other infectious disease pandemics. The COVID-19 pandemic exacerbates the impact of previous inequalities (Fig. 1), particularly among those already experiencing different types of barriers, like those with TB (Fig. 2). Therefore, mitigating social determinants - such as improved housing, reduced overcrowding, improved nutrition and increased economic and social resilience – diminishes the impact of infectious diseases, such as TB and COVID-19, even before the advent of effective medications.
What is there in common between tuberculosis and COVID-19

Much had been written in both social media and the scientific literature before the first cohorts of patients with TB and COVID-19 had been finally evaluated and described. We are still on the learning curve for COVID-19, while we know more about TB, which has affected mankind for a long time. A year into the beginning of the pandemic, COVID-19 has been responsible for roughly the same number of deaths caused by TB annually (approximately 1.8 million for the first vs 1.5 million for the latter in 2019) although COVID-19 as of January 10, 2020, had 8 times more cases than TB (approximately 86 million vs 10 million new TB cases in 2019).

They are both airborne-transmitted diseases, although SARS-CoV-2 is more infectious, and therefore needs very careful management of individual protection devices, as well as social distancing.

Signs and symptoms are largely the same, potentially challenging differential diagnosis. SARS-CoV-2 is also transmitted by asymptomatic individuals, a feature which makes it very transmissible and harder to control.

For both diseases, co-morbidities lead to increased vulnerability (including cancer; chronic lung and kidney diseases; smoking; alcohol use disorders; depression; HIV and other immunocompromising diseases and diabetes, among others).

Whilst, for TB, curative strategies are available, with success rates above 85% in drug-susceptible individuals (lower for those who are multidrug-resistant, in the order of 60%), several drugs are under evaluation to define an effective treatment for COVID-19.

Finally, both diseases have significant impact on health and social services and important economic implications, which for COVID-19 still need to be quantified. Additionally, scientific literature on the relevance of sequelae following the acute phase of COVID-19 is emerging and those can also be combined with the post-TB treatment sequelae.

Their impact on quality of life, the potential need for pulmonary rehabilitation, and long-term socioeconomic support are future challenges needing further evaluation.

How and what can we learn from good practices

COVID-19 represents an unprecedented challenge in modern public health practice. Having spread across most of the countries and having infected millions of individuals, this pandemic requires a coordinated, effective response without sacrificing quality or availability of other essential medical services. At first glance, COVID-19 transcends the traditional boundaries of socioeconomic and demographic status, with everybody seemingly at risk of falling ill. In reality though, COVID-19 is, like most infectious disease outbreaks, a pandemic that accelerates and compounds existing inequities.

TB infection and prevention programmes, as well as correlative health professionals, are uniquely prepared for this
challenge due to all the previous years fighting against this disease. Thus, these resources can and should be leveraged to mobilize already-trained health care workers to adapt existing TB programmes’ guidance; to implement the already available administrative and environmental controls; and to improve practices around the use of personal protective equipment.

Effective epidemic surveillance systems such as increasing mass testing capacity to self-isolate infected patients or implementing effective contact tracing through Bluetooth and/or GPS tracking (as for example Singapore, Portugal and South Korea did) can enable knowledge of infection among asymptomatic individuals.38–60

Individuals need to follow healthy hygene practices; stay at home when sick; observe physical distancing to lower the risk of disease spread; and use a cloth face-covering or mask in community settings when physical distancing cannot be maintained.32–34 Many countries quickly put in place economic support models to facilitate this, although coverage of such measures is still very limited.61 Here we can see that the concept of community vs individual is really important – if we as individuals comply with the rules, we can protect others.

Another great achievement that needs to be addressed as good practice and capability to respond in a time like this is related to the health system preparedness and capacity: building new hospitals; increasing intensive care unit bed numbers; resort to medical and nursing students and/or to retired health care workers.20,24,33 The improvement of community care capacity with hospital at home, distance monitoring with oximeter and home oxygen, are good examples of the capacity and resilience to fight against COVID-19 crisis.

In this sense, both diseases would gain from the use of capacity building efforts; improved surveillance and monitoring systems; and robust programmes and infrastructure already developed over many years of investment.33 An example is one of the TB outpatient centres in the Portuguese Northern Region that actively engaged with the premise of not leaving anyone behind, assembling a significant and rapid response to COVID-19, while ensuring that TB and other essential health services were maintained.62

Lessons learned and global health response

In recent years, the role of risk factors and social determinants of TB have been more intensively studied and the role of some highly prevalent determinants such as Human Immunodeficiency Virus (HIV), smoking, diabetes mellitus, alcohol use and under-nutrition have been highlighted. Others include overcrowding, housing conditions and economic deprivation. It has been shown that the highest TB incidence
geographic areas are also those with highest incidence of HIV infection, incarceration, overcrowding, unemployment and immigration.

Although TB outbreaks occur everywhere, available diagnosis and treatment ensure that people in richer countries mostly recover from the disease.\textsuperscript{62} COVID-19, with its current rate of spread, lack of treatment and natural immunity, is exploiting many of the same health, economic, and social inequities that TB has been doing for centuries. Additionally, the prioritization of human and material resources to fight the COVID-19 pandemic and the increased danger of co-infection with SARS-CoV-2 to those with TB pose further threats to TB control efforts.\textsuperscript{64} If those concerns are not addressed soon, COVID-19 could substantially reverse the gains achieved in TB control and worsen the epidemic in the coming months or years.\textsuperscript{65,66}

To date, the COVID-19 response has demonstrated that, with political will, prioritization and investments, it is possible for the international community to mobilize resources, accelerate scientific discovery, and deploy new public health tools to fight a pandemic.\textsuperscript{67} These same strategies can thus be employed for TB. However, the COVID-19 response, especially strict lock-downs and mobility restrictions, have also caused immense social and economic suffering and highlighted the need to strike a careful balance between immediate public health gains and unintended health and social side effects.

We have now a rare opportunity to seize the moment and use the attention garnered by this novel virus pandemic to ensure that new investments contribute, not only to the control of COVID-19, but also to strengthen the control of older challenges. Lessons learned from previous relevant public health programs would certainly benefit those at risk for COVID-19.

Final notes

Despite the rapidly increasing number of cases, the data needed to predict the impact of the COVID-19 pandemic on patients with TB infection and TB sequelae and to guide management in this particular context still lies ahead.

COVID-19, like TB, reminds us of the importance of prioritising health and allocating financial and human resources for universal health and social protection coverage and addressing the needs of vulnerable populations. The link between infectious disease and poverty is further recognised as such; increased investment in their control results in societal structural changes that benefit all if carefully planned and executed.

We need to get ready for the post-COVID-19 world, where people-centred health systems with community-driven interventions will become vital instruments towards achieving better health, economic and moral outcomes.

Authors’ contributions

All authors contributed substantially to the interpretation of the articles in analysis, critical discussion and revision of the manuscript, and approved its final version.

Financial support

None declared.

Ethical responsibilities

None declared.

Conflict of interest

The authors declare they have no conflicts of interest.

References

1. Alley C, Sommerfeld J. Infectious disease in times of social and ecological change. Med Anthropol. 2014;33:85–91.
2. Heesterbeek H, Anderson RM, Andreasen V, Bansal S, De Angelis D, Dye C, et al. Modeling infectious disease dynamics in the complex landscape of global health. Science. 2015;347:aaa4339.
3. Gottdenker NL, Streicker DG, Faust CL, Carroll CR. Anthropogenic land use change and infectious diseases: a review of the evidence. EcoHealth. 2014;11:619–32.
4. Jones KE, Patel NG, Levy HA, Storeygard A, Balk D, Gittleman JL, et al. Global trends in emerging infectious diseases. Nature. 2008;451:990–3.
5. Klepac P, Metcalf CJ, McLean AR, Hampson K. Towards the endgame and beyond: complexities and challenges for the elimination of infectious diseases. Philos Trans R Soc Lond B Biol Sci. 2013;368:20120137.
6. World Health Organization. Closing the gap in a generation: health equity through action on the social determinants of health. In: Final report of the Commission on Social Determinants of Health. 2008.
7. Lönnroth K, Tessier L, Hensing G, Behrendt C. Income security in times of ill health: the next frontier for the SDGs. BMJ Glob Health. 2020;5.
8. World Health Organization. Global tuberculosis report. Geneva, Switzerland; 2020.
9. Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major infectious diseases. Washington (DC): The International Bank for Reconstruction and Development/The World Bank; 2017.
10. Carter DJ, Glaziou P, Lönnroth K, Siroka A, Floyd K, Weil D, et al. The impact of social protection and poverty elimination on global tuberculosis incidence: a statistical modelling analysis of Sustainable Development Goal 1. Lancet Glob Health. 2018;6:e514–22.
11. World Health Organization. Sustainable health financing structures and universal coverage. Geneva; 2011.
12. World Health Organization. Agenda of the Sixty-seventh World Health Assembly. Geneva, Switzerland.
13. Rocha C, Montoya R, Zevallos K, Curatola A, Yng W, Franco J, et al. The Innovative Socio-economic Interventions Against Tuberculosis (ISIAT) project: an operational assessment. Int J Tuberc Lung Dis. 2011;15 Suppl. 2:50–7.
14. Upilekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new end TB strategy. Lancet. 2015;385:1799–801.
15. Ali M, Imam F, Malik S, Rk M, Kumar P, Garg A, et al. Effect of social factors on tuberculosis patients: a comprehensive illness behaviour study. Indian J Pharm Pract. 2013;4:123–6.
16. Baldwin MR, Yori PP, Ford C, Moore DAJ, Gilman RH, Vidal C, et al. Tuberculosis and nutrition: disease perceptions and health
seeking behavior of household contacts in the Peruvian Amazon. Int J Tuberc Lung Dis. 2004;8:1484–91.
17. Godfrey-Faussett P, Kaunda H, Kamanga J, van Beers S, van Cleef M, Kumwenda-Pihiri R, et al. Why do patients with a cough delay seeking care at Lusaka urban health centres? A health systems research approach. Int J Tuberc Lung Dis. 2002;6:796–805.
18. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med. 2009;68:2240–6.
19. Mandavilli A. ‘The biggest monster’ is spreading. And it’s not the coronavirus: The New York Times. Available from: https://www.nytimes.com/2020/08/03/health/coronavirus-tuberculosis-aids-malaria.html [03.08.20].
20. Ong CWM, Goletti D. Impact of the global COVID-19 outbreak on the management of other communicable diseases. Int J Tuberc Lung Dis. 2020;24:547–8.
21. Abdool Karim Q, Abdool Karim SS. COVID-19 affects HIV and tuberculosis care. Science. 2020;369:366–8.
22. European Commission. The organization of resilient health and social care following the COVID-19 pandemic – opinion of the Expert Panel on effective ways of investing in Health (EXPH). Luxembourg: Publications Office of the European Union; 2020.
23. Lustig N, Tommasi M. Covid-19 and social protection of poor and vulnerable groups in Latin America: a conceptual framework. In: Regional Bureau of Latin America and the Caribbean of the United Nations Development Program. Editor: UNDP Latin America and the Caribbean. 2020.
24. Buonconsalo D, Iodice F, Sorba Biala J, Goletti D. COVID-19 effects on tuberculosis care in Sierra Leone. Pulmonology. 2021;27:67–9.
25. Visca D, Ong CWM, Tiberi S, Centis R, D’Ambrosio L, Chen B, et al. Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects. Pulmonology. 2021.
26. Migliori GB, Thong PM, Akkerman O, Alfvenaar JW, Álvarez-Navascués F, Assaso-Neino MM, et al. Worldwide effects of coronavirus disease pandemic on tuberculosis services, January–April 2020. Emer Infec Dis. 2020;26:2709–12.
27. McNeely CL, Schintler LA, Stabile B. Social determinants and COVID-19 disparities: differential pandemic effects and dynamics. World Med Health Policy. 2020;12:206–17.
28. Tediosi F, Lönnroth K, Pablos-Méndez A, Raviglione M. Build back stronger universal health coverage systems after the COVID-19 pandemic: the need for better governance and linkage with universal social protection. BMJ Glob Health. 2020;5.
29. Abrams EM, Szeffer SJ. COVID-19 and the impact of social determinants of health. Lancet Respir Med. 2020;8:659–61.
30. Butler-Jones D, Wong T. Infectious disease, social determinants and the need for intersectoral action. Can Commun Dis Rep. 2016;42:Suppl. 1:S118–20.
31. Cortegiani A, Ippolito M, Greco M, Granoine V, Protti A, Gregoretti C, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2021;27:52–66.
32. Ong CWM, Migliori GB, Raviglione M, MacGregor-Skinner G, Sotgiu G, Alfvenaar JW, et al. Epidemic and pandemic viral infections: impact on tuberculosis and the lung: a consensus by the World Association for Infectious Diseases and Immunological Disorders (WAID), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J. 2020;56;2001727.
33. Dara M, Sotgiu G, Reichler MR, Chiang CY, Chee CBE, Migliori GB. New diseases and old threats: lessons from tuberculosis for the COVID-19 response. Int J Tuberc Lung Dis. 2020;24:544–5.
34. Alagna R, Besozzi G, Codecasa LR, Gori A, Migliori GB, Raviglione M, et al. Celebrating World Tuberculosis Day at the time of COVID-19. Eur Respir J. 2020;55:2000650.
35. de Souza CDF, Coutinho HS, Costa MM, Magalhães M, Carmo RF. Impact of COVID-19 on TB diagnosis in Northeastern Brazil. Int J Tuberc Lung Dis. 2020;24:1220–2.
36. Echeverría G, Espinoza W, de Waard JH. How TB and COVID-19 compare: an opportunity to integrate both control programmes. Int J Tuberc Lung Dis. 2020;24:971–4.
37. Kadota JL, Reza TF, Nalugwa T, Kityamuwesi A, Nanyunja G, Kiwanuka N, et al. Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic. Int J Tuberc Lung Dis. 2020;24:1212–4.
38. Keddy KH, Migliori GB, Van Der Walt M. Developing health policies in patients presenting with SARS-CoV-2: consider tuberculosis. Lancet Glob Health. 2020;8:e1357–8.
39. Meneguim AC, Rebelo L, Das M, Ravi S, Mathur T, Mankar S, et al. Adapting TB services during the COVID-19 pandemic in Mumbai, India. Int J Tuberc Lung Dis. 2020;24:1119–21.
40. Wilson FA, Miller TL, Stimpson JP. COVID-19 and TB control in immigrant communities. Int J Tuberc Lung Dis. 2020;24:975–7.
41. Wu Z, Chen J, Xia Z, Pan Q, Yuan Z, Zhang W, et al. Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China. Int J Tuberc Lung Dis. 2020;24:1122–4.
42. Zhou S, Van Staden Q, Toska E. Resource reprioritisation amid competing health risks for TB and COVID-19. Int J Tuberc Lung Dis. 2020;24:1215–6.
43. Adewole OO. Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria. Int J Tuberc Lung Dis. 2020;24:981–2.
44. Fatima R, Yaqoob A. In Reply: How TB and COVID-19 compare: an opportunity to integrate both control programmes. Int J Tuberc Lung Dis. 2020;24:1227–8.
45. Shahariarirad R, Fallahi MJ. TB and the COVID-19 pandemic: brothers in arms against lung health. Int J Tuberc Lung Dis. 2020;24:1126–7.
46. van der Walt M, Keddy KH. How COVID-19 can instruct TB research: ensuring the safety of researchers exposed to infectious disease. Int J Tuberc Lung Dis. 2020;24:978–80.
47. Gupta N, Ish P, Gupta A, Malhotra H, Caminero JA, Singla R, et al. A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis. Eur Respir J. 2020;56.
48. Motta I, Centis R, D’Ambrosio L, García-Garcia JM, Goletti D, Gualano G, et al. Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology. 2020;26:233–40.
49. Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Raviglione MC. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J. 2020;56.
50. Sunil S, Manu MS, Rakesh PS, Shibu B. Mortality among individuals with TB-COVID-19 co-infection: Initial observations from Kerala, India. IJTLID. 2021 [In press].
51. Tadolini M, Codecasa LR, García-Garcia JM, Blanc FX, Borisov S, Alfvenaar JW, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020;56(1), 2001398.
52. Belli S, Balbi B, Prince I, Cattaneo D, Masocco F, Zaccaria S, et al. Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation. Eur Respir J. 2020;56(4), 2000296.
53. Munoz-Torrico M, Cid-Juárez S, Gochicoa-Rangel L, Torre-Bouscolet L, Salazar-Lezama MA, Villarreal-Velarde H, et al. Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2020;24:700–5.
54. Visca D, Centis R, Munoz-Torrico M, Pontali E. Post-tuberculosis sequelae: the need to look beyond treatment outcome. Int J Tuberc Lung Dis. 2020;24:761–2.
55. Visca D, Zampogna E, Sotgiu G, Centis R, Saderi L, D’Ambrosio L, et al. Pulmonary rehabilitation is effective in patients with
tuberculosis pulmonary sequelae. Eur Respir J. 2019;53(3), 1802184.
56. Visca D., Centis R., D'Ambrosio L., Muñoz-Torrico M., Chakaya
JM, Tiberi S., et al. The need for pulmonary rehabilitation fol-
lowing tuberculosis treatment. Int J Tuberc Lung Dis. 2020;
24:720–2.
57. Johns Hopkins Coronavirus Resource Center. Johns
Hopkins Coronavirus Resource Center. Available from:
https://coronavirus.jhu.edu/.
58. BBC news. Singapore hands out coronavirus tracing
devices 2021. Available from: https://www.bbc.com/
news/business-53216450.
59. The National Law Review. Privacy vs. pandemic control in
South Korea; 2020. Available from: https://www.natlawreview
.com/article/privacy-vs-pandemic-control-south-korea
60. Direção Geral da Saúde. Plataforma Autoreport e Trace
COVID-19; 2020. Available from: https://www.sns.gov.pt/
noticias/2020/12/17/plataforma-autoreport-e-trace-covid-19/
61. M.T. Stern-Plaza, L. Frota and K. Lönnroth. Turning the COVID-
19 crisis into an opportunity: health protection and sickness
benefits to face the COVID 19 pandemic, 2021. Available from:
https://www.youtube.com/watch?v=ayilOneT6JA&feature
=youtu.be.
62. Aguiar A., Furtado I., Sousa M., Pinto M., Duarte R. Changes to TB
care in an outpatient centre during the COVID-19 pandemic. Int
J Tuberc Lung Dis. 2020;25(2), 163b-166(4).
63. World Health Organization. WHO Tuberculosis Factsheet.
Geneva; 2020.
64. Chen Y., Wang Y., Fleming J., Yu Y., Gu Y., Liu C., et al. Active
or latent tuberculosis increases susceptibility to COVID-19 and
disease severity. MedRxv. 2020, 2020.03.10.20033795.
65. Boffa J., Mhlaba T., Sulis G., Moyos S., Sifumba Z., Pai M., et al. COVID-
19 and tuberculosis in South Africa: a dangerous combination.
S Afr Med J. 2020;110:341–2.
66. Pang Y., Liu Y., Du J., Gao J., Li L. Impact of COVID-19 on tubercu-
losis control in China. Int J Tuberc Lung Dis. 2020;24:545–7.
67. Oga-Omenka B., Pharm C., Akinrin B., Pharm AT, Boffa J., Heitkamp
P, et al. Commentary: lessons from the COVID-19 global health
response to inform TB case finding. Healthcare. 2020:100487.